Literature DB >> 10896650

Changes in the antigenicity of a hepatitis B virus mutant stemming from lamivudine therapy.

W N Chen, C J Oon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10896650      PMCID： PMC89956          DOI： 10.1128/AAC.44.6.1765-1765.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  10 in total

Review 1.  Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance.

Authors:  S A Locarnini
Journal:  Hepatology       Date:  1998-01       Impact factor: 17.425

2.  The HBV-producing cell line HepG2-4A5: a new in vitro system for studying the regulation of HBV replication and for screening anti-hepatitis B virus drugs.

Authors:  L Weiss; A S Kekulè; U Jakubowski; E Bürgelt; P H Hofschneider
Journal:  Virology       Date:  1996-02-01       Impact factor: 3.616

3.  Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine.

Authors:  R Ling; D Mutimer; M Ahmed; E H Boxall; E Elias; G M Dusheiko; T J Harrison
Journal:  Hepatology       Date:  1996-09       Impact factor: 17.425

4.  Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine.

Authors:  J Gauthier; E J Bourne; M W Lutz; L M Crowther; J L Dienstag; N A Brown; L D Condreay
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

5.  Vaccine-induced escape mutant of hepatitis B virus.

Authors:  W F Carman; A R Zanetti; P Karayiannis; J Waters; G Manzillo; E Tanzi; A J Zuckerman; H C Thomas
Journal:  Lancet       Date:  1990-08-11       Impact factor: 79.321

Review 6.  Human hepatitis B virus mutants: significance of molecular changes.

Authors:  W N Chen; C J Oon
Journal:  FEBS Lett       Date:  1999-06-25       Impact factor: 4.124

7.  Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.

Authors:  M M Bartholomew; R W Jansen; L J Jeffers; K R Reddy; L C Johnson; H Bunzendahl; L D Condreay; A G Tzakis; E R Schiff; N A Brown
Journal:  Lancet       Date:  1997-01-04       Impact factor: 79.321

8.  Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir.

Authors:  C J Oon; W N Chen; N Lim; S Koh; G K Lim; A L Leong; G S Tan
Journal:  Antiviral Res       Date:  1999-04       Impact factor: 5.970

9.  Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues.

Authors:  S L Doong; C H Tsai; R F Schinazi; D C Liotta; Y C Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

10.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Authors:  C L Lai; R N Chien; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; P C Wu; J C Dent; J Barber; S L Stephenson; D F Gray
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245
  10 in total
  2 in total

1.  Hepatitis B virus X protein interacts with beta5 subunit of heterotrimeric guanine nucleotide binding protein.

Authors:  Siew Hui Lwa; Wei Ning Chen
Journal:  Virol J       Date:  2005-08-31       Impact factor: 4.099

2.  Characterization of the "a" determinant region of the hepatitis B virus genome in Iranian patients at different clinical phases of chronic infection.

Authors:  Sara Romani; Seyed Masoud Hosseini; Seyed Reza Mohebbi; Andre Boonstra; Armin Hosseini Razavi; Afsaneh Sharifian
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2018
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.